OCUGEN, INC. Restricted Cash
OCUGEN, INC. (OCGN) had Restricted Cash of $320.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2026-08-06
- 2026-06-30: Restricted Cash $320.00K.
- 2026-03-31: Restricted Cash $318.00K.
- 2025-12-31: Restricted Cash $316.00K.
- 2025-09-30: Restricted Cash $314.00K.
| Period end | Restricted Cash | Restricted Cash as first filed |
|---|---|---|
| 2026-06-30 | $320.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $318.00K 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $316.00K 10-K · filed 2026-03-04 | |
| 2025-09-30 | $314.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $312.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $309.00K 10-Q · filed 2026-05-08 | |
| 2024-12-31 | $307.00K 10-K · filed 2026-03-04 | |
| 2024-09-30 | $305.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $302.00K 10-Q · filed 2025-08-04 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-05 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |
| 2019-03-31 | $137.00K 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $100.00K 10-Q · filed 2019-08-09 | |
| 2018-09-30 | $100.00K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $137.00K 10-Q · filed 2019-08-09 | $100.00K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $137.00K 10-Q · filed 2019-05-15 | $100.00K 10-Q · filed 2018-05-10 |
| 2018-01-31 | $150.00K 8-K/A · filed 2019-10-07 | |
| 2017-12-31 | $100.00K 10-Q · filed 2018-11-08 | |
| 2017-05-31 | $100.00K 8-K/A · filed 2019-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |